Junichi Mukai

Junichi Mukai


Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 May 2017 in Journal of Pharmaceutical Health Care and Sciences
Verified
Journal Article
Open access
PDF file
JMJunichi Mukai
Junichi Mukai
YTYuta Tsuge
Yuta Tsuge
MYMichiko Yamada
Michiko Yamada
KOKatsuya Otori
Katsuya Otori
KAKoichiro Atsuda
Koichiro Atsuda
Randomized controlled trials (RCTs) reported that resistant dextrin (RD) exerted pleiotropic effects on humans. However, limited information is available on the effects of RD for weight loss. We conducted a systematic review with a meta-analysis to summarize the available literature and compare the efficacy of RD for weight loss with that of a placebo in overweight adults. We searched the electronic databases MEDLINE, EMBASE, The Cochrane Central Register of Controlled Trials (CENTRAL), CINAHL, Web of Science, ClincalTrials.gov, and Japana Centra Revuo Medicina (Ichushi-web) for studies from their onset to November 2016, and there was no language restriction. Trials were included if they were RCTs (1) comparing the effects of RD with a placebo in adults (18 years or older), (2) reporting body mass index, and (3) including overweight/obese subjects as defined by the authors of RCTs. The weighted mean difference with a 95% confidence interval (CI) was calculated using a random-effects model. Of the 484 studies retrieved, 3 RCTs involving 275 subjects were included in our review. The durations of RCTs ranged between 8 and 12 weeks. All RCTs were conducted in Asian countries. RD significantly improved body mass index [mean difference −0.39 (95% CI −0.57 to −0.21) kg/m2, p < 0.01] and body weight [mean difference −0.81 (95% CI −0.93 to −0.69) kg, p < 0.01] in overweight adults. Our review suggests that RD exerts beneficial effects for weight loss in overweight adults. More RCTs with different populations and longer follow-ups are needed in order to confirm that supplementation with RD has beneficial effects for weight loss in overweight adults. We consider this review to provide important information for the future submission of food with health claims.

29 June 2021 in Scientific Reports
Verified
Journal Article
Open access
PDF file
JMJunichi Mukai
Junichi Mukai
SKShinya Kanno
Shinya Kanno
RKRie Kubota
Rie Kubota
The safety profiles of sodium-glucose co-transporter 2 (SGLT2) inhibitors may depend on races/ethnicities. We aimed to assess the safety profiles of SGLT2 inhibitors in Japanese patients with diabetes mellitus (DM). The electronic databases MEDLINE, CENTRAL, and Ichushi-web were searched for studies with no language restriction from their inception to August 2019. Trials were included in the analysis if they were randomized controlled trials (RCTs) comparing the effects of SGLT2 inhibitors with a placebo in Japanese patients with DM > 18 years and reporting HbA1c and at least 1 adverse event. We calculated risk ratios with 95% CIs and used a random-effects model. Of the 22 RCTs included in our review, only 1 included patients with type 1 DM. The durations of RCTs ranged between 4 and 24 weeks. In comparison with a placebo, SGLT2 inhibitors were associated with similar risks of hypoglycemia, urinary tract infection, genital infection, hypovolemia, and fracture. The outcomes of treatment with SGLT2 inhibitors among Japanese patients with DM suggest favorable safety profiles. However, further evidence from studies with a longer duration, involving more diverse populations, such as patients with different types of DM, or including individual SGLT2 inhibitors is needed to resolve the limitations of the present study.

14 March 2020 in Journal of Pharmaceutical Health Care and Sciences
Verified
Journal Article
Open access
PDF file
JMJunichi Mukai
Junichi Mukai
AYAyano Yoshiyama
Ayano Yoshiyama
RKRie Kubota
Rie Kubota
Few systematic reviews have examined the effects of sodium-glucose co-transporter 2 inhibitors (SGLT2is) on lipid profiles in Asian patients with type 2 diabetes mellitus. We conducted a systematic review with a meta-analysis to summarize the available literature and confirm the effects of SGLT2is on lipid profiles in these patients. We searched the electronic databases MEDLINE, CENTRAL, and Ichushi-web for studies from the dates of their earliest publication to July 2018, and there was no language restriction. Trials were included if they were randomized controlled trials (RCTs) (1) comparing the effects of SGLT2is with a placebo in Asian patients with type 2 diabetes mellitus (18 years or older), and (2) reporting HbA1c and at least one lipid parameter, such as triglycerides (TG), high-density lipoprotein cholesterol (HDL-C), or low-density lipoprotein cholesterol (LDL-C). The weighted mean difference with a 95% confidence interval (CI) was calculated using a random-effects model. Among the 630 studies retrieved, 17 RCTs that included 4485 patients were ultimately included in our review. Fourteen RCTs were conducted in Japan. The durations of RCTs ranged between 12 and 24 weeks. SGLT2is significantly improved HbA1c [mean difference − 0.80 (95%CI − 0.96 to − 0.64)%, p < 0.00001], TG [mean difference − 16.42 (95%CI − 22.71 to − 10.12) mg/dL, p < 0.00001], and HDL-C [mean difference 3.36 (95%CI 2.73 to 3.98) mg/dL, p < 0.00001], but significantly deteriorated LDL-C [mean difference 3.00 (95%CI 1.18 to 4.82) mg/dL, p < 0.001]. The LDL-C/HDL-C ratio was not significantly different between SGLT2is and a placebo [mean difference − 0.01 (95%CI − 0.08 to 0.06), p < 0.74]. The present results suggest that in Asian patients with type 2 diabetes mellitus, TG and HDL-C values were better, while LDL-C values were worse with SGLT2is than with a placebo. However, the negative impact of SGLT2is on lipid profiles was modest. Further RCTs with a longer duration or conducted in other Asian countries are needed to provide further evidence to support the clinical relevance of changes in lipid profiles. The present results will be informative for SGLT2is users with concerns regarding the effects of SGLT2is on lipid profiles.

29 May 2025 in Diabetology International
Verified
Journal Article
Open access
PDF file
JMJunichi Mukai
Junichi Mukai
MAManabu Akazawa
Manabu Akazawa
YYYuji Yoshiyama
Yuji Yoshiyama
RKRie Kubota
Rie Kubota
The aims of this retrospective study were to examine persistence/adherence rates to sodium-glucose co-transporter 2 inhibitors (SGLT2i) monotherapy in patients with type 2 diabetes (T2DM) and identify factor(s) affecting persistence/adherence. Claims data on patients with T2DM newly using SGLT2i monotherapy from the JMDC database between October 2017 and September 2020 were analyzed. Persistence without a 90-day gap was calculated from the index date until the time of discontinuation of SGLT2i in a 1-year follow-up. Adherence was calculated using the proportion of days covered (PDC). Baseline characteristics were examined as potential factors affecting persistence/adherence using a multivariate logistic method. The present study identified 2172 new users of SGLT2i monotherapy. The persistence rate to SGLT2i after 365 days was 61.0%. Mean PDC was 71.2%, and 58.3% of patients adhered to treatment. A multivariate logistic regression analysis showed that an older age, hypertension, dyslipidemia, and hyperuricemia were associated with a lower risk of the discontinuation of SGLT2i monotherapy, while an older age, hypertension, dyslipidemia, and hyperuricemia were associated with a lower risk of poor adherence. The present study identified several factors that reduced the risk of discontinuation/poor adherence to SGLT2i monotherapy in patients with T2DM. An older age, hypertension, dyslipidemia, and hyperuricemia were common factors for a lower risk of discontinuation/poor adherence.

29 June 2021 in Pharmacy
Verified
Journal Article
Open access
PDF file
RKRie Kubota
Rie Kubota
JMJunichi Mukai
Junichi Mukai
MYMichiko Yamada
Michiko Yamada
YYYurika Yoshino
Yurika Yoshino
NONakaba Okamura
Nakaba Okamura
This study aimed to evaluate the usefulness of the practicum as well as assess the knowledge, skills, and various specific realizations that the students gained from it. A total of 244 students role-played a scenario in which a pharmacist visited a patient at home and provided pharmaceutical management services. After completing the practicum, the students completed (i) a questionnaire survey consisting of six questions that assessed their level of understanding of the role of pharmacists in home medical care and (ii) a rubric survey that evaluated their learning achievement. In addition, they submitted practicum portfolios describing the patients’ living conditions, physical conditions, and background as well as the services that required consideration of said variables. Their responses to the portfolio item “What were noticed through the practicum” were analyzed using the grounded theory approach. After the practicum, 45% and 53% of the students reported having a full and partial understanding of a pharmacists’ role in home medical care. The students’ mean ± standard deviation rubric score was 3.0 ± 0.4. They classified monitoring drug use, support for improving medication adherence, and observation to identify side effects early as major service categories in home medical care. The practicum led the students to perceive the need for communication with patients and various healthcare professionals to improve their readiness for practical training.

15 September 2023 in Journal of Pharmaceutical Health Care and Sciences
Verified
Journal Article
Open access
PDF file
JMJunichi Mukai
Junichi Mukai
NONakaba Okamura
Nakaba Okamura
YSYuki Saito
Yuki Saito
RKRie Kubota
Rie Kubota
Background: We conducted a systematic review and meta-analysis to summarize the available literature and comprehensively appraise the renal profiles of sodium-glucose cotransporter 2 inhibitors (SGLT2i) in Japanese patients with type 2 diabetes mellitus (T2DM). Methods: The electronic databases MEDLINE, Ichushi-web, and ClinicalTrials.gov were searched for studies without language restrictions from their inception until 20 July 2023 and CENTRAL until 21 September 2021. Studies were included if they were double-masked randomized controlled trials (RCTs) (1) including Japanese patients with T2DM aged > 18 years who received SGLT2i or a placebo, (2) reporting at least one renal outcome of serum creatinine or the estimated glomerular filtration rate (eGFR), and (3) with a follow-up of > 12 weeks. Cross-over and open label trials were excluded. The risk of bias based on the Cochrane risk-of-bias tool for randomized trials (RoB 2) was appraised. We computed the weighed mean difference with 95%CI for each renal outcome and used a random-effects model (inverse variance method). Results: We ultimately retrieved 13 RCTs including 2687 individuals in our review. The durations of RCTs ranged between 12 and 104 weeks. Only one trial had a longer duration of more than one year. Ten out of 13 RCTs reported serum creatinine, while nine included eGFR. Serum creatinine and eGFR were slightly worse with SGLT2i than with a placebo [mean difference 0.01 (95%CI 0.00 to 0.02) mg/dL, p = 0.002, mean difference − 1.30 (95%CI -2.23 to -0.37) mL/min/1.73 m2, p = 0.006, respectively]. Merged results revealed insignificant heterogeneity (I2 < 30%). Conclusion: These results suggest that SGLT2i slightly worsens serum creatinine and eGFR in Japanese patients with T2DM. However, since the durations of most RCTs were short, the effects of eGFR in particular may be transient. Further evidence is needed from rigorous studies that focus on renal outcomes with a longer duration to confirm the present results.